California Plan to Maximize Impact of $3.9 Billion for Stem Cell/Gene Therapies Clears Critical Hurdle
Major goals? Fifteen to 20 new, late stage clinical trials, six to 10 rare disease treatments ready for commercialization
SOUTH SAN FRANCISCO — A key panel of directors of the California stem cell and gene therapy agency unanimously endorsed a sweeping plan today to maximize the impact of its last $3.9 billion, including an attempt to make multimillion-dollar treatments affordable and propel 15 to 20 therapies into late-stage clinical trials.
The action this morning came after several important numbers were added for the first time to four of the proposed new priorities for the $12 billion California Institute for Regenerative Medicine (CIRM), as the agency is formally known. The numbers in the following goals are new as of today.
“Advance at least 6-10 rare disease projects to BLA (a step prior to commercialization)”
“Propel 15-20 therapies targeting diseases affecting Californians to late-stage trials”
“Catalyze the identification and validation of at least 5-8 novel targets and biomarkers, ensuring integration into preclinical or clinical research for diseases in California”
“Accelerate development and utilization of 5-8 technologies that demonstrate improvements in safety, efficacy, and quality of cell and gene therapies”
How much CIRM plans to spend on its new priorities
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.